Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Costa V, Canver MC, Harris RM, Rand JH, Greenblatt MB. Accelerated thrombin times are associated with thrombotic risk. Am J Hematol. 2020;95(5):E113-E114.

Chiang GC, Pisapia DJ, Liechty B, Magge R, Ramakrishna R, Knisely J, et al. The Prognostic Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas. J Neuroimaging. 2020;30(6):901-909.

Ma LX, Craig KM, Mosquera JM, Robinson BD, Scherr DS, Del Pizzo J, et al. Contemporary Results and Clinical Utility of Renal Mass Biopsies in the Setting of Ablative Therapy: A single center experience. Cancer Treat Res Commun. 2020;25:100209.

Yang HS, Racine-Brzostek SE, Karbaschi M, Yee J, Dillard A, Steel PA, et al. Testing-on-a-probe biosensors reveal association of early SARS-CoV-2 total antibodies and surrogate neutralizing antibodies with mortality in COVID-19 patients. medRxiv. 2020.

Li S, Kendall J, Park S, Wang Z, Alexander J, Moffitt A, et al. Copolymerization of single-cell nucleic acids into balls of acrylamide gel. Genome Res. 2020;30(1):49-61.

Reynders M, Matsuura BS, Bérouti M, Simoneschi D, Marzio A, Pagano M, et al. PHOTACs enable optical control of protein degradation. Sci Adv. 2020;6(8):eaay5064.

Zhong E, Solomon JP, Cheng E, Baum J, Song W, Hoda SA. Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity. Am J Surg Pathol. 2020;44(8):1092-1103.

Hadi K, Yao X, Behr JM, Deshpande A, Xanthopoulakis C, Tian H, et al. Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell. 2020;183(1):197-210.e32.

Thoren KL, Avecilla ST, Klimek V, Goss C. A novel method for the laboratory workup of anaphylactic transfusion reactions in haptoglobin-deficient patients. Transfusion. 2020;60(4):682-687.

Chaekal O-, Scaradavou A, Frenet EM, Albano MS, Cushing M, Desai P, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020;4(20):5146-5156.